Time course of cognitive dysfunction and biochemical marker of CNS lesions S100ß in coronary artery bypass graft

Objective: to study cognitive functions and level of proteins of acute brain damage in a group of patients receiving Cerebrolysin, and in a comparison group in the pre- and postoperative period of coronary artery bypass graft surgery.

Materials and methods. The open-label randomized comparative controlled parallel study included 60 men. The average age in the group of patients receiving the therapy with Cerebrolysin was 61.5 (57÷66) years, and was – 61 (56÷65) years (р > 0.05) in the comparison group.

Results. Groups differed statistically significantly according to the left ventricular ejection fraction: 56 (48÷64) – in the group of comparison, 61 (59÷65) – in the group of patients receiving therapy with Cerebrolysin (p < 0.05). In the group of patients receiving Cerebrolysin, an increase in score according to MMSE (р < 0.01) was noted from 25 (24÷27) to 26.2 (24–28) points, and in the group without brain neuroprotection in the preoperative period a decrease in score according the Mini-Mental State Examination was revealed to be from 25.5 (25÷27) to 25 (23÷27) (р < 0.01). Clinical value of the level of protein S100ß as a biological indicator of postoperative cognitive dysfunction after cardiac surgery was ambiguous and required additional research.

Conclusion. Brain neuroprotection with use of Cerebrolysin (authors’ schema) promoted not only maintenance but also improvement of cognitive functions and decreased the likelihood of complications in mental activity after coronary artery bypass graft surgery under conditions of artificial circulation and cold cardioplegia, particularly in patients with a high risk for their development.

postoperative cognitive dysfunction, coronary artery bypass graft, protein S100ß, Cerebrolysin

1. Medvedeva L.A., Zagorulko O.I., Belov Yu.V., Peshkova O.P., Bogopolskaya O.M. Cognitive postoperative dysfunction in cardiac surgery. Kardiologiya i serdechno-sosudistaya khirurgiya – Cardiology and cardiovascular surgery. 2012; 5 (4): 46–54 (in Russ.).

2. Bedford P.D. Adverse cerebral effects of anaesthesia on old people. Lancet. 1955; 269 (6884): 259–63.

3. Förstl H., Maelicke A., Weichel C. Demenz: Taschenatlas spezial Thieme Georg Verlag. 2008: 100.

4. Girard T.D., Pandharipande P.P., Ely E.W. Delirium in the intensive care unit. Crit. Care. 2008; 12 (3): 3. DOI: 10.1186/cc6149.

5. Chernov V.I., Efimova N.Yu., Efimova I.Yu., Ahmedov S.H., Lishmanov Yu.B. Short-term and long-term cognitive function and cerebral perfusion in off-pump and on-pump coronary artery bypass patients. European Journal of Cardio-Thoracic Surgery. 2006; 29 (1): 74–81.

6. Christensen M.C., Previgliano I., Capparelli F.J., Lerman D., Lee W.C., Wainsztein N.A. Acute treatment costs of intracerebral hemorrhage and ischemic stroke in Argentina. Acta Neurol. Scand. 2009; Apr. 119 (4): 246–253. DOI: 10.1111/j.1600-0404.2008.01094x.

7. Skvortsova V.I., Stakhovskaya L.V., Gubsky L.V., Shamalov N.A., Tikhonova I.V., Smychkov A.S. A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zh. Nevrol. Psikhiatr. Im. S.S. Korsakova – S.S. Korsakov Journal of Neurology and Psychiatry. 2004; (11): 51–55 (in Russ.).

8. Ubhi K., Rockenstein E., Vazquez-Roque R., Mante M., Inglis C., Patrick C., Adame A., Fahnestock M., Doppler E., Novak P., Moessler H., Masliah E. Cerebrolysin Modulates Pronerve Growth Factor/Nerve Growth Factor Ratio and Ameliorates the Cholinergic Deficit in a Transgenic Model of Alzheimer’s Disease. J. of Neurosci Res. 2013; Feb. 91 (2): 167–177. DOI: 10.1002/jnr.23142.

9. Zhang C., Chopp M., Cui Y., Wang L., Zhang R., Zhang L., Lu M., Szalad A., Doppler E., Hitzl M., Zhang Z.G. Cerebrolysin Enhances Neurogenesis in the Ischemic Brain and Improves Functional Outcome After Stroke. J. of Neurosci. Res. 2010; Nov. 88 (15): 3275–3281. DOI: 10.1002/jnr.22495.

10. Hartbauer M., Hutter-Paier B., Skofitsch G., Windisch M. Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons. J. Neural. Transm. 2001; 108 (4): 459–473.

11. Rockenstein E., Mante M., Adame A., Crews L., Moessler H., Masliah E. Effects of Cerebrolysin on neurogenesis in an APP trangenic model of Alzheimer’s disease. Acta Neuropathol. 2007; Mar. 113 (3): 265–275.

12. Ubhi K., Rockenstein E., Doppler E., Mante M., Trejo M., Paulino A., Moessler H., Adame A., Patrick Ch., Crews L., Masliah E. Neurofibrillary and neurodegenerative pаthology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects in Cerebrolysin. Acta Neuropathol. 2009; Jun. 117 (6): 699–712. DOI: 10.1007/s00401-009-0505-4.

13. Sugita Y., Kondo T., Kanazawa A., Itou T., Mizuno Y. Protective effect of FPF 1070 (Cerebrolysin) on delayed neuronal death in the gerbil – detection of hydroxyl radicals with salicylic acid. No To Shinkei. 1993; 45 (4): 325–331.

14. Alvarez X.A., Lombardi V.R., Fernández-Novoa L., Garcнa M., Sampedro C., Cagiao A., Cacabelos R., Windisch M. Cerebrolysin reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection. J. Neuronal. Transm. Suppl. 2000; 59: 281–292.

15. Lang W., Stadler C.H., Poljakovic Z., Fleet D., Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke. Int. J. Stroke. 2013; Feb. 8 (2): 95–104. DOI: 10.1111/j.1747-4949.2012.00901.x.

16. Heiss W.D., Brainin M., Bornstein N.M., Tuomilehto J., Hong Z. Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012; Mar. 43 (3): 630–636. DOI: 10.1161/STROKEAHA.111.628537.

17. Ladurner G., Kalvach P., Moessler H. Cerebrolysin Study Group. Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomized controlled trial. J. Neural. Transm. (Vienna). 2005; Mar. 112 (3): 415–428.

18. Jauch E.C., Saver J.L., Adams H.P. Jr., Bruno A., Connors J.J., Demaerschalk B.M., Khatri P., McMullan P.W. Jr., Qureshi A.I., Rosenfield K., Scott P.A., Summers D.R., Wang D.Z., Wintermark M., Yonas H. American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2013; Mar. 44 (3): 870–947. DOI: 10.1161/STR.0b013e318284056a.

19. Shamalov N.A., Stakhovskaya L.V., Burenchev D.V., Kichuk I.V., Tvorogova T.V., Botsyna A.Iu., Smychkov A.S., Kerbikov O.B., Moessler H., Novak P., Skvortsov V.I. The effect of cerebrolysin in dosage 50 ml on the volume of lesion in ischemic stroke. Zh. Nevrol. Psikhiatr. Im. S.S. Korsakova – S.S. Korsakov Journal of Neurology and Psychiatry. 2010; 110 (12): 34–37 (in Russ.).

20. Fedin A.I., Generalov V.O., Mishnyakova L.P., Moiseyeva T.V., Sadykov T.R. Dynamics of cognitive functions in patients with chronic cerebral ischemia on the background of parenteral application of cerebrolysin. Difficult Patient. 2008; 6 (12): 51–54 (in Russ.).

21. Ueno T., Iguro Y., Yamamoto H., Sakata R., Kakihana Y., Nakamura K. Serial measurement of serum S-100B protein as a marker of cerebral damage after cardiac surgery. Ann. Thorac. Surg. 2003; Jun. 75 (6): 1892–1897.

22. Jönsson H., Johnsson P., Bäckström M., Alling C., Dautovic-Bergh C., Blomquist S. Controversial significance of early S100B levels after cardiac surgery. BMC Neurol. 2004; Dec. 4 (1): 24.

23. Basile A.M., Fusi C., Conti A.A., Paniccia R., Trefoloni G., Pracucci G., Di Carlo A., Noferi D., Carbonetto F., Pretelli P., Calamai G., Vaccari M., Abbate R., Inzitari D. S-100 protein and neuron-specific enolase as markers of subclinical cerebral damage after cardiac surgery: preliminary observation of a 6-month follow-up study. Eur. Neurol. 2001; 45 (3): 151–159.

24. Westaby S., Saatvedt K., White S., Katsumata T., van Oeveren W., Bhatnagar N.K., Brown S., Halligan P.W. Is there a relationship between serum S-100beta protein and neuropsychologic dysfunction after cardiopulmonary bypass? J. Thorac. Cardiovasc. Surg. 2000; Jan. 119 (1): 132–137.

25. Liu Y., Buck D.C., Neve K.A. Novel interaction of the dopamine D2 receptor and the Ca2+ binding protein S100B: role in D2 receptor function. Mol. Pharmacol. 2008 Aug; 74 (2): 371–378. DOI: 10.1124/mol.108.044925.

26. Trailin A.V., Levada O.A. Protein S100B: neurobiology, a value for neurological and psychiatric pathology. International neurological journal. 2009; 1: 166–175 (in Russ.).

27. Rothermundt M., Arolt V., Wiesmann M., Missler U., Peters M., Rudolf S., Kirchner H. S-100B is increased in melancholic but not in non-melancholic major depression. J. Affect Disord. 2001; Sep. 66 (1): 89–93.

28. Grabe H.J., Ahrens N., Rose H.J., Kessler C., Freyberger H.J. Neurotrophic factor S100beta in major depression. Neuropsychobiology. 2001; 44 (2): 88–90.

29. Cata J.P., Abdelmalak B., Farag E. Neurological biomarkers in the perioperative period. Br. J. Anaesth. 2011; Dec. 107 (6): 844–858. DOI: 10.1093/bja/aer338.

30. Beck A.T., Beck R.W. Screening depressed patients in family practice. A rapid technic. Postgraduate Med. 1972; Dec. 52 (6): 81–85.

31. Sheehan D.V. The Sheehan Patient Rated Anxiety Scale. J. Clin. Psychiatry. 1999; 60: 63–64.

32. Folstein M.F., Folstein S.E., McHugh P.R. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975; Nov. 12 (3): 189–98.

33. Hachinski V.C., Iliff L.D., Zilhka E., Du Boulay G.H., McAllister V.L., Marshall J., Russell R.W., Symon L. Cerebral blood flow in dementia. Arch Neurol. 1975; Sep. 32 (9): 632–637.

34. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. Suppl. 1987; 334: 1–100.